T2 Biosystems, Inc. is a commercial‐stage diagnostics company focused on developing and marketing innovative, rapid diagnostic products designed to improve patient outcomes and reduce healthcare costs. The company’s proprietary T2 Magnetic Resonance (T2MR) technology enables direct detection of pathogens and biomarkers in whole blood without the need for culture, delivering results in hours rather than days. T2 Biosystems’ core mission is to provide clinicians with faster, actionable data to guide treatment decisions, particularly in the management of sepsis, bloodstream infections and other life‐threatening conditions.
The flagship product, the T2Dx® Instrument, serves as the platform for all T2 assays. The company’s first FDA‐cleared test, the T2Candida® Panel, identifies five major species of Candida directly from patient blood samples. Building on this success, T2 Biosystems has obtained FDA clearance for the T2Bacteria® Panel, which detects six common bacterial pathogens associated with bloodstream infections. Additional assays in the pipeline include panels for antimicrobial resistance markers and emerging infectious threats, underscoring the company’s commitment to expanding the clinical utility of its T2MR platform.
T2 Biosystems conducts commercial operations across the United States and European markets, operating under both FDA clearance and CE Mark authorizations. Its products are primarily targeted to hospital laboratories, molecular diagnostic centers and critical care units. By offering rapid testing that bypasses lengthy culture steps, the company aims to support antimicrobial stewardship programs and help healthcare providers reduce hospital stays, lower treatment costs and combat the rise of drug‐resistant infections.
Founded in 2006 based on technology developed in academic research laboratories, T2 Biosystems is headquartered in Lexington, Massachusetts. The company is led by a management team with extensive experience in diagnostics, life sciences and regulatory affairs, with John McDonough serving as President and Chief Executive Officer. Since its inception, T2 Biosystems has raised multiple rounds of financing and advanced its platform from proof‐of‐concept through regulatory clearance and commercial launch, positioning it as a pioneer in rapid molecular diagnostics.
AI Generated. May Contain Errors.
